Brentuximab vedotin plus ESHAP: complete remission in R/R Hodgkin lymphoma
Managing problems in treating CLL
Using models to predict progression in follicular lymphoma
Dendritic cell vaccine for MM: progress so far
Are newer, targeted agents better for the management of untreated CLL than chemoimmunotherapy?